Toxicity management of angiogenesis inhibitors: resolution of expert panel
On 22 June 2017 in St. Petersburg the expert panel was held on the topic Management of toxicity of angiogenesis inhibitors, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of ef...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Endocrinology Research Centre
2017-12-01
|
| Series: | Эндокринная хирургия |
| Subjects: | |
| Online Access: | https://surg-endojournals.ru/serg/article/viewFile/9472/7052 |
| Summary: | On 22 June 2017 in St. Petersburg the expert panel was held on the topic Management of toxicity of angiogenesis inhibitors, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of efficacy and safety of new target drugs in the treatment of these diseases. The reports and discussions of experts raised the following questions: 1. Own experience of using lenvatinib in patients with differentiated thyroid cancer refractory to therapy with radioactive iodine and kidney cancer. 2. Profile of efficacy and safety of modern targeted therapy with multikinase inhibitors. 3. Prophylaxis and management of predictable toxicity. |
|---|---|
| ISSN: | 2306-3513 2310-3965 |